Tag
GTX-102 missed all its goals in a Phase 3 study for the rare disorder, wiping out a would-be blockbuster and pushing the company toward significant cost cuts.
The Department of Veterans Affairs’ electronic health-record overhaul has ballooned from $10 billion to $27 billion — and lawmakers say they learned of it from the news, not the company.
The deal licenses HMPL-A830, an antibody-delivered therapy designed to shut down both EGFR and KRAS — a driver mutation in many colorectal, lung and pancreatic cancers.
The company helps patients steer through cancer care — and is now building a broader oncology group backed by Humana, CVS and JPMorgan’s Morgan Health.
The deal buys rights to an early-stage “tri-specific” antibody built to hit B cells — drivers of many autoimmune conditions — from multiple angles at once.
The state accuses pharmacy-benefit managers Express Scripts and Prime Therapeutics of an arrangement that drove down what pharmacies get paid — by as much as 80% on some drugs.
The TYK2 inhibitor failed all its main and secondary goals in systemic lupus — the latest setback for a drug class that has struggled to crack the disease.
The deal adds a platform that selectively destroys the rogue antibodies behind conditions like Graves’ disease — without broadly suppressing the immune system.